ClinicalTrials.gg
CompletedNCT03439254REVERSEUpdated Oct 23, 2023Results posted

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

A Phase 3 interventional study of Obeticholic acid (10 mg) and Obeticholic acid (10 mg to 25 mg) in Compensated Cirrhosis and Nonalcoholic Steatohepatitis, sponsored by Intercept Pharmaceuticals. Completed at 192 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Intercept Pharmaceuticals (part of Alfasigma S.p.A.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
919
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
17th of 460
919 · median 56
Started
2017
with 25 others
Phase 3
29 of 547
7 open now
Registered
230th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 17th largest by enrollment of the 460 interventional ones that give a count, is one of 26 that started in 2017, is one of 29 in phase 3, and was the 230th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

03

Conditions studied

  • Compensated Cirrhosis
  • Nonalcoholic Steatohepatitis

Keywords

  • Compensated Cirrhosis
  • Nonalcoholic Steatohepatitis
  • Fatty Liver Disease
  • NASH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Subjects with a confirmed diagnosis of NASH and a fibrosis score of 4 based upon the NASH CRN scoring system determined by central reading

Key exclusion criteria:

  1. Current or past history of a clinically evident hepatic decompensation event, such as ascites, hepatic encephalopathy (HE), or variceal bleeding
  2. Current or past history of CP score ≥7 points
  3. Model for End-stage Liver Disease (MELD) score > 12
  4. ≥ 5 X
  5. Calculated \<60mL/min using Cockcroft-Gault method
  6. (HbA1c) ≥ 9.5 %
  7. Evidence of other known forms of chronic liver disease such as alcoholic liver disease, , , PBC, PSC, hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)
  8. History of liver transplant, or current placement on a liver transplant list
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
919 participants (actual)

Study arms

  • Experimental
    Obeticholic Acid (OCA) 10 mg

    10 mg OCA for up to 18 months

    Drug: Obeticholic acid (10 mg)

  • Experimental
    Obeticholic Acid (OCA) 10 mg to 25 mg

    10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study

    Drug: Obeticholic acid (10 mg to 25 mg)

  • Placebo comparator
    Placebo

    Placebo for up to 18 months

    Drug: Placebo

Interventions

  • Tablets administered orally once daily.

    Also known as: OCA, 6alpha-ethylchenodeoxycholic acid (6-ECDCA), INT-747

  • Tablets administered orally once daily.

    Also known as: OCA, 6alpha-ethylchenodeoxycholic acid (6-ECDCA), INT-747

  • DrugPlacebo

    Tablets administered orally once daily.

06

What researchers measure

Primary outcomes

  1. DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)

    Fibrosis stage was evaluated by NASH Clinical Research Network(CRN)Fibrosis Staging System with stages:0=no fibrosis;1=perisinusoidal/periportal;1A=mild,zone 3,perisinusoidal;1B=moderate,zone 3,perisinusoidal;1C=portal/periportal;2=perisinusoidal and portal/periportal;3=bridging fibrosis;4=cirrhosis.No worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade as per scoring in relevant nonalcoholic fatty liver disease activity score (NAS) categories.NAS is semiquantitative scoring system based on unweighted sum of:steatosis (0=\<5% to 3=\>66%),lobular inflammation(0=no foci to 3=\>4 foci/200x),hepatocellular ballooning(0=none to 2=many cells/prominent ballooning)scores.Total scale range:0-12;0:no features of fatty liver disease and 12:highest degree of fatty liver disease.Higher scores:worse symptoms.Responders:did not discontinue treatment due to Adverse event(AE) or did not die and had evaluable post-Baseline biopsy assessment

    Time frame: Up to 18 months

  2. OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

    Time frame: Up to 12 months

  3. OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)

    Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled transient elastography (TE) method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. Baseline was defined as the last value collected prior to the first administration of the investigational product (IP). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to Month 12

  4. OLE Phase: Fibrosis-4 (FIB-4) at Baseline

    FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, alanine aminotransferase (ALT) and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, Aspartate aminotransferase (AST) and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[Units per Liter {U/L}\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.

    Time frame: Baseline (Day 1)

  5. OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline

    ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised hyaluronic acid (HA), tissue inhibitor of metalloproteinase (TIMP1) and procollagen III N-terminal peptide (PIIINP). Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.

    Time frame: Baseline (Day 1)

  6. OLE Phase: Number of Participants Reporting All-cause Mortality

    All-cause mortality is defined as death due to any cause. Number of participants reporting all-cause mortality is presented

    Time frame: Up to Month 12

  7. OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related Death

    Adjudication was performed under the review of Hepatic Safety Adjudication Committee (HSAC) of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for the following is presented: Ascites (secondary to cirrhosis and requiring medical intervention), Hepatocellular carcinoma (HCC) and non-liver related death.

    Time frame: Up to 12 months

  8. OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score

    The Child-Pugh classification was a scoring system used for the classification of the severity of cirrhosis. It included three continuous variables (bilirubin, albumin, and international normalized ratio) and two discrete variables (ascites and encephalopathy). Each variable was scored 1-3 with 3 indicating most severe derangement. The determination of Child-Pugh score ranged from 5 to 15. The higher the score, the sicker the participant. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for worsening of Child-Pugh score is presented.

    Time frame: Up to 12 months

  9. OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15

    MELD was a scoring system for assessing the severity of chronic liver disease and to assess prognosis and suitability for liver transplantation. It uses the participant's values for total bilirubin, serum creatinine, and the international normalized ratio for prothrombin time to predict survival. MELD score ranges from 6 (less ill) to 40 (gravely ill) with scores and mortality probability being: Score 40=71.3% mortality; Scores 30-39=52.6% mortality; Scores 20-29=19.6% mortality; Scores10-19=6.0% mortality; Score 9 or less=1.9% mortality. Higher scores indicated greater disease severity. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for MELD score ≥15 is presented.

    Time frame: Up to 12 months

Secondary outcomes

  1. DB Phase: Change From Baseline to Month 18 in LSM

    Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled TE method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. The principal comparison was at Month 18. Baseline was defined as the last value collected prior to the first administration of the IP. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to Month 18

  2. DB Phase: FIB-4 at Baseline

    FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, ALT and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, AST and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.

    Time frame: Baseline (Day 1)

  3. DB Phase: ELF at Baseline

    ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised HA, TIMP1 and PIIINP. Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.

    Time frame: Baseline (Day 1)

07

Results

Posted Oct 23, 2023

Participant flow

The study was conducted at a total of around 286 centers.

Double-blind Phase (18 Months)
Participant flow — Double-blind Phase (18 Months)
MilestoneDB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
Started313296310000
Completed284274275000
Not completed292235000
Withdrew: Adverse event111215000
Withdrew: Covid-19 non adverse event (ae) related issues100000
Withdrew: Death122000
Withdrew: Lost to follow-up015000
Withdrew: Non-compliance with study drug100000
Withdrew: Participant moved to kansas100000
Withdrew: Site cover and participant was not willing to be transferred100000
Withdrew: Stopped investigational product (ip) due to an ae in australia010000
Withdrew: Drug holiday001000
Withdrew: Spouse underwent surgery and participant was unable to take ip regularly001000
Withdrew: Site closure001000
Withdrew: Physician decision001000
Withdrew: Progressive disease100000
Withdrew: Withdrawal by subject1269000
Open Label Extension Phase (12 Months)
Participant flow — Open Label Extension Phase (12 Months)
MilestoneDB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
Started000231221207
Completed000215208192
Not completed000161315
Withdrew: Adverse event000857
Withdrew: Bariatric surgery000101
Withdrew: Covid-19 non-ae related issues000001
Withdrew: Lost to follow-up000020
Withdrew: Increase cr from baseline000010
Withdrew: Medical reasons by sponsor000001
Withdrew: Physician decision000100
Withdrew: Progressive disease000120
Withdrew: Withdrawal by subject000535

Outcome measures

PrimaryDB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)

Fibrosis stage was evaluated by NASH Clinical Research Network(CRN)Fibrosis Staging System with stages:0=no fibrosis;1=perisinusoidal/periportal;1A=mild,zone 3,perisinusoidal;1B=moderate,zone 3,perisinusoidal;1C=portal/periportal;2=perisinusoidal and portal/periportal;3=bridging fibrosis;4=cirrhosis.No worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade as per scoring in relevant nonalcoholic fatty liver disease activity score (NAS) categories.NAS is semiquantitative scoring system based on unweighted sum of:steatosis (0=\<5% to 3=\>66%),lobular inflammation(0=no foci to 3=\>4 foci/200x),hepatocellular ballooning(0=none to 2=many cells/prominent ballooning)scores.Total scale range:0-12;0:no features of fatty liver disease and 12:highest degree of fatty liver disease.Higher scores:worse symptoms.Responders:did not discontinue treatment due to Adverse event(AE) or did not die and had evaluable post-Baseline biopsy assessment

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)
ParticipantsDB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mg
DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)313337
Statistical analysis
  • DB: Placebo vs DB: OCA 10 Milligrams (mg) · Cochran-Mantel-Haenszel · p = 0.6172 · Response ratio(mantel-haenszel estimate): 1.13 · 95% CI 0.71 to 1.79Treatment / Placebo Response Ratio = Percentage of Responders in Active Treatment Arm / Percentage of Responders in Placebo, stratified by Baseline diabetes status (yes/no).
  • DB: Placebo vs DB: OCA 10 mg Titrated to OCA 25 mg · Cochran-Mantel-Haenszel · p = 0.4184 · Response ratio(mantel-haenszel estimate): 1.20 · 95% CI 0.77 to 1.89Treatment / Placebo Response Ratio = Percentage of Responders in Active Treatment Arm / Percentage of Responders in Placebo, stratified by Baseline diabetes status (yes/no).
PrimaryOLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
AEs199213197
SAEs265048
PrimaryOLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)

Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled transient elastography (TE) method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. Baseline was defined as the last value collected prior to the first administration of the investigational product (IP). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to Month 12
Reported as:
Median · Kilopascal (kPa)
OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)
Kilopascal (kPa)OLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)-2.10 (-7.40 to 3.40)-2.90 (-7.75 to 1.35)-3.45 (-7.85 to 0.75)
PrimaryOLE Phase: Fibrosis-4 (FIB-4) at Baseline

FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, alanine aminotransferase (ALT) and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, Aspartate aminotransferase (AST) and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[Units per Liter {U/L}\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.

Time frame:
Baseline (Day 1)
Reported as:
Mean · Ratio
OLE Phase: Fibrosis-4 (FIB-4) at Baseline
RatioOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
OLE Phase: Fibrosis-4 (FIB-4) at Baseline2.179 ± 1.03422.267 ± 0.95672.266 ± 1.0867
PrimaryOLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline

ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised hyaluronic acid (HA), tissue inhibitor of metalloproteinase (TIMP1) and procollagen III N-terminal peptide (PIIINP). Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.

Time frame:
Baseline (Day 1)
Reported as:
Mean · Scores on a scale
OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline
Scores on a scaleOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline10.46 ± 0.93310.50 ± 0.94010.48 ± 0.821
PrimaryOLE Phase: Number of Participants Reporting All-cause Mortality

All-cause mortality is defined as death due to any cause. Number of participants reporting all-cause mortality is presented

Time frame:
Up to Month 12
Reported as:
Count of participants · Participants
OLE Phase: Number of Participants Reporting All-cause Mortality
ParticipantsOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
OLE Phase: Number of Participants Reporting All-cause Mortality101
SecondaryDB Phase: Change From Baseline to Month 18 in LSM

Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled TE method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. The principal comparison was at Month 18. Baseline was defined as the last value collected prior to the first administration of the IP. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to Month 18
Reported as:
Median · Kilopascal (kPa)
DB Phase: Change From Baseline to Month 18 in LSM
Kilopascal (kPa)DB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mg
DB Phase: Change From Baseline to Month 18 in LSM-0.50 (-5.20 to 5.60)-3.10 (-7.30 to 3.20)-2.90 (-8.10 to 2.50)
SecondaryDB Phase: FIB-4 at Baseline

FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, ALT and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, AST and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.

Time frame:
Baseline (Day 1)
Reported as:
Mean · Ratio
DB Phase: FIB-4 at Baseline
RatioDB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mg
DB Phase: FIB-4 at Baseline2.279 ± 1.10912.475 ± 1.93072.405 ± 1.1630
SecondaryDB Phase: ELF at Baseline

ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised HA, TIMP1 and PIIINP. Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.

Time frame:
Baseline (Day 1)
Reported as:
Mean · Scores on a scale
DB Phase: ELF at Baseline
Scores on a scaleDB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mg
DB Phase: ELF at Baseline10.50 ± 0.92110.60 ± 0.92010.61 ± 0.867
PrimaryOLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related Death

Adjudication was performed under the review of Hepatic Safety Adjudication Committee (HSAC) of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for the following is presented: Ascites (secondary to cirrhosis and requiring medical intervention), Hepatocellular carcinoma (HCC) and non-liver related death.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related Death
ParticipantsOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
Ascites (secondary to cirrhosis and requiring medical intervention)102
HCC311
Non-liver related death101
PrimaryOLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score

The Child-Pugh classification was a scoring system used for the classification of the severity of cirrhosis. It included three continuous variables (bilirubin, albumin, and international normalized ratio) and two discrete variables (ascites and encephalopathy). Each variable was scored 1-3 with 3 indicating most severe derangement. The determination of Child-Pugh score ranged from 5 to 15. The higher the score, the sicker the participant. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for worsening of Child-Pugh score is presented.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score
ParticipantsOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score012
PrimaryOLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15

MELD was a scoring system for assessing the severity of chronic liver disease and to assess prognosis and suitability for liver transplantation. It uses the participant's values for total bilirubin, serum creatinine, and the international normalized ratio for prothrombin time to predict survival. MELD score ranges from 6 (less ill) to 40 (gravely ill) with scores and mortality probability being: Score 40=71.3% mortality; Scores 30-39=52.6% mortality; Scores 20-29=19.6% mortality; Scores10-19=6.0% mortality; Score 9 or less=1.9% mortality. Higher scores indicated greater disease severity. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for MELD score ≥15 is presented.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15
ParticipantsOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15001

Adverse events

Collected over Up to 18 months for DB phase and Up to 1 year for OLE phase. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB: Placebo4/312 (1.3%)43/312 (13.8%)290/312 (92.9%)
DB: OCA 10 Milligrams (mg)3/295 (1%)49/295 (16.6%)276/295 (93.6%)
DB: OCA 10 mg Titrated to OCA 25 mg3/309 (1%)46/309 (14.9%)291/309 (94.2%)
OLE: OCA 10 mg (DB Placebo)1/231 (0.4%)26/231 (11.3%)199/231 (86.1%)
OLE: OCA 10 mg (DB OCA 10 mg)0/221 (0%)50/221 (22.6%)213/221 (96.4%)
OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)1/207 (0.5%)48/207 (23.2%)197/207 (95.2%)
Most frequent serious events
Showing 10 of 195
Most frequent serious events
EventDB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
BradycardiaCardiac disorders0/3120/2950/3092/2316/2218/207
COVID-19 pneumoniaInfections and infestations0/3122/2953/3093/2312/2217/207
Procedural painInjury, poisoning and procedural complications1/3120/2953/3090/2310/2214/207
COVID-19Infections and infestations0/3121/2951/3090/2310/2213/207
DyspnoeaRespiratory, thoracic and mediastinal disorders1/3120/2953/3090/2310/2213/207
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3123/2950/3092/2312/2210/207
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/3121/2953/3090/2310/2212/207
Cerebrovascular accidentNervous system disorders0/3120/2953/3090/2310/2212/207
Abdominal pain upperGastrointestinal disorders2/3120/2951/3090/2310/2212/207
Urinary tract infectionInfections and infestations0/3121/2952/3090/2311/2212/207
Most frequent other events
Showing 10 of 38
Most frequent other events
EventDB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgOLE: OCA 10 mg (DB Placebo)OLE: OCA 10 mg (DB OCA 10 mg)OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg)
PruritusSkin and subcutaneous tissue disorders98/312120/295177/30972/23197/221120/207
NauseaGastrointestinal disorders43/31232/29548/30919/23128/22139/207
Urinary tract infectionInfections and infestations29/31244/29527/30913/23138/22131/207
COVID-19Infections and infestations0/3120/2950/3097/23121/22131/207
Abdominal pain upperGastrointestinal disorders29/31230/29523/30912/23131/22118/207
Low density lipoprotein increasedInvestigations5/31234/29533/30911/23131/22117/207
ArthralgiaMusculoskeletal and connective tissue disorders35/31222/29528/30915/23124/22129/207
ConstipationGastrointestinal disorders20/31228/29533/30912/23126/22128/207
FatigueGeneral disorders35/31227/29536/30915/23127/22127/207
DiarrhoeaGastrointestinal disorders38/31228/29522/30912/23124/22120/207

Baseline characteristics

Intent-To-Treat (ITT) Population: included all randomized participants.

Age, Continuous
Age, Continuous(Years)DB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgTotal
Mean59.5 ± 8.9960.1 ± 8.7060.1 ± 8.6759.9 ± 8.78
Sex: Female, Male
Sex: Female, Male(Participants)DB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgTotal
Female212184209605
Male101112101314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgTotal
Hispanic or Latino445255151
Not Hispanic or Latino246217233696
Unknown or Not Reported23272272
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB: PlaceboDB: OCA 10 Milligrams (mg)DB: OCA 10 mg Titrated to OCA 25 mgTotal
American Indian or Alaska Native33410
Asian85518
Native Hawaiian or Other Pacific Islander0134
Black or African American46414
White272254272798
More than one race1214
Unknown or Not Reported25252171
08

Study locations

192 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Objective GI d/b/a North Alabama GI Research Center
    Madison, Alabama 35758, United States
  • Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Arizona Liver Health
    Glendale, Arizona 85306, United States
  • The Institute for Liver Health
    Tucson, Arizona 85712, United States
  • Liver Wellness Center
    Little Rock, Arkansas 72205, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • University of California, San Francisco-Fresno
    Fresno, California 93701, United States
  • Scripps Whittier Diabetes Institute
    La Jolla, California 92037, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • Cedars-Sinani Medical Center
    Los Angeles, California 90048, United States
  • Palmtree Clinical Research, INC.
    Palm Springs, California 92262, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Kaiser Permanente Sacramento Medical Center
    Sacramento, California 95825, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • University of Colorado Denver and Hospital
    Aurora, Colorado 80045, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • South Denver Gastroenterology, PC
    Englewood, Colorado 80113, United States
  • Innovative Medical Research of South Florida, Inc.
    Aventura, Florida 33180, United States
  • Hi Tech and Global Research LLC
    Coral Gables, Florida 33134, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • UF Health Jacksonville-Gastroenterology Emerson
    Jacksonville, Florida 32207, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Sensible Healthcare, LLC
    Ocoee, Florida 34761, United States
  • Innovation Medical Research Center
    Palmetto Bay, Florida 33157, United States
  • Gastroenterology Associates of Pensacola, PA
    Pensacola, Florida 32503, United States
  • Tampa General Medical Group
    Tampa, Florida 33606, United States
  • Guardian Angel Research Center, INC
    Tampa, Florida 33614, United States
  • Florida Medical Clinic, P.A
    Zephyrhills, Florida 33542, United States
  • Summit Clinical Research, LLC
    Athens, Georgia 30607, United States
  • The Emory Clinic (TEC)
    Atlanta, Georgia 30322, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Grand Teton Research Group, PLLC
    Idaho Falls, Idaho 83404, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Aquiant Research
    New Albany, Indiana 47150, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kansas Medical Clinic
    Topeka, Kansas 66606, United States
  • University of Louisville, Clinical Trials Unit
    Louisville, Kentucky 40202, United States
  • Tandem Clinical Research, LLC
    Marrero, Louisiana 70072, United States
  • Delta Research Partners, LLC
    Monroe, Louisiana 71201, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Louisiana Research Center
    Shreveport, Louisiana 71105, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Lahey Hospital & Medical Center
    Burlington, Massachusetts 01805, United States
  • UMass Memorial Health Care
    Worcester, Massachusetts 01655, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center
    Wyoming, Michigan 49519, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • Minnesota Gastroenterology, P.A.
    Saint Paul, Minnesota 55114, United States
  • Southern Therapy and Advanced Research (STAR) LLC
    Jackson, Mississippi 39216, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • CHI Health Alegent Creighton Clinic
    Omaha, Nebraska 68124, United States
  • Sierra Clinical Research
    Las Vegas, Nevada 89106, United States
  • Amici GI-LLC
    Martinsville, New Jersey 08836, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • University at Buffalo, Clinical and Translational Research Center
    Buffalo, New York 14203, United States
  • Ichan School of Medicine at Mount Sinai Beth Israel
    New York, New York 10003, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Asheville Gastroenterology Associates, P.A.
    Asheville, North Carolina 28801, United States
  • University of North Carolina at Chapel Hill, School of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroenterology & Hepatology, PLLC
    Charlotte, North Carolina 28207, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Carolinas Center for Liver Disease/Carolinas HealthCare System
    Huntersville, North Carolina 28078, United States
  • Carolinas Health Care System Center for Liver Disease
    Huntersville, North Carolina 28078, United States
  • Diabetes & Endocrinology Consultants, PC
    Morehead City, North Carolina 28557, United States
  • Trial Management Associates, LLC
    Wilmington, North Carolina 28403, United States
  • Dayton Gastroenterology, Inc.
    Beavercreek, Ohio 45440, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Northeast Clinical Research Center, LLC
    Bethlehem, Pennsylvania 18017, United States
  • The Pennsylvania State University and the Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Einstein Healthcare Network
    Philadelphia, Pennsylvania 19141, United States
  • UPMC - Center for Liver Diseases at the Thomas E. Starzl Institute
    Pittsburgh, Pennsylvania 15213, United States
  • University Gastroenterology
    Providence, Rhode Island 02905, United States
  • Ralph H. Johnson Veterans Affairs Medical Center
    Charleston, South Carolina 29401, United States
  • SCTR Research Nexus
    Charleston, South Carolina 29425, United States
  • Rapid City Medical Center LLP
    Rapid City, South Dakota 57701, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Associates in Gastroenterology, PLC
    Hermitage, Tennessee 37076, United States
  • Johnson City Medical Center
    Johnson City, Tennessee 37604, United States
  • Methodist Healthcare University Hospital
    Memphis, Tennessee 38104, United States
  • Quaility Medical Research, PLLC
    Nashville, Tennessee 37211, United States
  • Vanderbilt University Medical Center - Digestive Disease Center
    Nashville, Tennessee 37232, United States
  • Texas Clinical Research Institute LLC
    Arlington, Texas 76012, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Liver Center of Texas
    Dallas, Texas 75234, United States
  • Texas Digestive Disease Consultants
    Dallas, Texas 75246, United States

Showing the first 100 of 192 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Sep 2022, 60 months.

Results were first posted in Oct 2023, 1 year 1 month after primary completion.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2018
First posted
Feb 20, 2018
StartActual
Aug 30, 2017
Primary completionActual
Sep 8, 2022
CompletionActual
Sep 8, 2022
Results first posted
Oct 23, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03439254
Responsible party
Sponsor
First posted
Feb 20, 2018
Start date
Aug 30, 2017
Primary completion
Sep 8, 2022
Completion
Sep 8, 2022
Results posted
Oct 23, 2023
Last update
Oct 23, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obeticholic acid

Start the discussion